Catalyst Pharmaceuticals (CPRX) Research & Development (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Research & Development came in at $2.7 million in Q1 2026, down 31.54% YoY from $3.9 million in Q1 2025, and up 47.26% on a QoQ basis from $1.8 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Research & Development (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 17 years of Research & Development data on file, last reported at $2.7 million in Q1 2026.
- Quarterly Research & Development fell 31.54% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 17.71% YoY) and the FY2025 annual result came in at $12.7 million, changed 0.48% from the prior year.
- Research & Development grew to $2.7 million in Q1 2026, from $1.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $83.7 million in Q3 2023 to a low of $1.8 million in Q4 2025.
- A 5-year average of $8.3 million and a median of $3.6 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development surged 906.76% — and 2024, when it tumbled 96.07%.
- Tracing CPRX's Research & Development over 5 years: stood at $4.1 million in 2022, then plunged by 51.82% to $2.0 million in 2023, then surged by 92.6% to $3.8 million in 2024, then tumbled by 52.42% to $1.8 million in 2025, then surged by 47.26% to $2.7 million in 2026.
- The last three Research & Development figures came in at $2.7 million (Q1 2026), $1.8 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 2.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.66 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 4.36 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.28 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Dec 31, 2023 | 1.97 Mn |
| Sep 30, 2023 | 83.66 Mn |
| Jun 30, 2023 | 3.95 Mn |
| Mar 31, 2023 | 3.56 Mn |
| Dec 31, 2022 | 4.09 Mn |
| Sep 30, 2022 | 8.31 Mn |
| Jun 30, 2022 | 3.98 Mn |
| Mar 31, 2022 | 3.40 Mn |
| Dec 31, 2021 | 4.99 Mn |
| Sep 30, 2021 | 4.49 Mn |
| Jun 30, 2021 | 4.45 Mn |